Petvivo Hldgs Inc Stock Price, News & Analysis

PetVivo (OTCQX: PETV) launched PetVivo.ai on November 25, 2025, an AI platform the company says reduces veterinary customer acquisition costs to $42.53 (a 50–89% reduction versus typical $80–$400) and generates qualified leads for $3 each. The platform uses nine AI agents across discovery, campaign management, engagement, analytics, content, reputation, compliance, ROI optimization and integration.

Beta economics (50 practices) reported a median of 47 new clients over 6 months, $3 lead cost, 80–90% gross margins, 25:1 LTV/CAC, 1 month payback and a Professional price of $1,999/month. PetVivo projects $12M ARR (Year 1), $180M ARR (Year 3) and $360M ARR (Year 5) from target practice adoption.

PetVivo (OTCQX: PETV) announced publication of Digital Landia’s technical whitepaper validating the AgenticPet AI Framework that underpins PetVivo’s exclusive 10-year white-label licensing agreement signed October 2025.

The whitepaper describes a production-ready, multi-agent veterinary AI architecture with claimed 90–98% client acquisition cost reduction, five patent-pending innovations, enterprise features (end-to-end encryption, blockchain audit trails, HIPAA-aligned privacy), and 99.9% uptime design. PetVivo targets a Q1 2026 dual launch with B2C and B2B platforms and pre-launch registration opening January 2026.

PetVivo (OTCQX: PETV) reported fiscal Q2 2026 results for the quarter ended Sept 30, 2025, with revenues of $303,000, up 51% year-over-year and a record second fiscal quarter. Gross profit was $220,000 with a 72.6% gross margin. Operating loss widened to $2.1 million, and net loss increased to $3.0 million or $0.11 per share. Cash totaled $768,000 and total liabilities fell 79% to $1.1 million. Company cited product launches (PrecisePRP), distributor expansion, international entry, strategic partnerships, and AI and biomaterials collaborations as drivers of growth and future commercialization.

PetVivo (OTCQX: PETV) will host a conference call on Friday, November 14, 2025 at 5:00 p.m. ET to discuss fiscal second quarter results for the period ended September 30, 2025. A press release with the financial results will be issued prior to the call.

Dial-in details: toll-free +1 669 444 9171, Conference ID 87234562707, Passcode 396948. A live webcast and replay will be available via the company’s Investors page at petvivo.com/investors.

PetVivo Holdings (OTCQX: PETV; OTCID PETVW) announced that Josh Ruben has joined its Board of Directors effective Oct. 28, 2025. Ruben is Managing Director of Life Sciences at Trinity Capital and previously spent 12 years in investment banking, most recently as Head of Life Science Tools and Diagnostics coverage at RBC Capital Markets.

The company highlighted Ruben’s experience in healthcare finance, venture lending, and executing multi‑billion‑dollar M&A and capital transactions as qualifications to support PetVivo’s veterinary Spryng® product and potential expansion into human therapeutics.

PetVivo Holdings (OTCQX: PETV) entered an exclusive 10-year white-label B2B licensing agreement with Digital Landia for Agentic Pet AI, a two-sided platform linking Gen Z pet parents to veterinary clinics. The deal includes 1 million restricted shares and covers 5 patent-pending innovations and 9 AI diagnostic agents. PetVivo cites a Q1 FY2026 revenue growth of 141% YoY and record fiscal 2025 revenue of $1.13 million. The companies plan a dual-platform launch in Q1 2026 targeting a $4.9 billion US veterinary AI market and 30,000+ clinics, claiming potential client acquisition costs of $1.50–$5.00.

PetVivo (OTCQX: PETV) announced a Vendor Partner Agreement with Veterinary Growth Partners (VGP) on October 16, 2025 to expand commercial access to its veterinary therapeutics.

Under the agreement VGP — which serves over 7,300 veterinary members — will promote PetVivo’s flagship products Spryng with OsteoCushion Technology and PrecisePRP across its network, streamlining purchasing and access for member practices. PrecisePRP is an off-the-shelf, leucoreduced allogeneic PRP product with 4 billion platelets per vial (500,000 platelets/μL) and <1500 WBC/μL. The agreement aims to accelerate national availability and product adoption for non-pharmaceutical regenerative treatments.

PetVivo Holdings (OTCQX: PETV) has successfully executed note conversion agreements with four existing shareholders, converting $2,018,155 of outstanding debt into 3,669,806 shares of common stock. The debt consisted of $1,850,000 in principal plus $168,155 in accrued interest, with conversion prices ranging from $0.50 to $0.75 per share.

The converted debt proceeds were used to commercialize the company's flagship products: SPRYNG® with OsteoCushion® Technology, an injectable veterinary device for joint pain management, and PrecisePRP®, an off-the-shelf platelet-rich plasma product for veterinary use. This debt elimination strengthens PetVivo's balance sheet and enables greater focus on strategic growth initiatives.

PetVivo Animal Health (OTCQX: PETV) has launched three new RACE-approved continuing education (CE) courses for veterinary professionals, each offering 1.0 credit hour. The courses focus on osteoarthritis (OA) management and regenerative therapies for both small animal and equine practices.

The educational program includes three distinct courses: an introductory course on OA care in small animals, an advanced course on joint injections, and a specialized course on regenerative therapies in equine practice. These courses combine scientific research with practical instruction and are available at no cost to veterinary professionals through PetVivo's online learning platform.